2.36
-0.12(-4.84%)
Currency In USD
| Previous Close | 2.48 |
| Open | 2.48 |
| Day High | 2.52 |
| Day Low | 2.34 |
| 52-Week High | 7.13 |
| 52-Week Low | 0.46 |
| Volume | 1.15M |
| Average Volume | 13.6M |
| Market Cap | 705.63M |
| PE | -4.21 |
| EPS | -0.56 |
| Moving Average 50 Days | 2.61 |
| Moving Average 200 Days | 1.63 |
| Change | -0.12 |
If you invested $1000 in ProKidney Corp. (PROK) since IPO date, it would be worth $233.43 as of September 30, 2025 at a share price of $2.36. Whereas If you bought $1000 worth of ProKidney Corp. (PROK) shares 3 years ago, it would be worth $261.93 as of September 30, 2025 at a share price of $2.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
GlobeNewswire Inc.
Aug 27, 2025 11:30 AM GMT
WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior m
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
GlobeNewswire Inc.
Jul 15, 2025 11:30 AM GMT
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated approval and
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
GlobeNewswire Inc.
Jul 09, 2025 11:30 AM GMT
WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior m